Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

医学 吉西他滨 鼻咽癌 内科学 顺铂 肿瘤科 临床研究阶段 化疗 放射治疗
作者
Wenfeng Fang,Yunpeng Yang,Yuxiang Ma,Shaodong Hong,Lizhu Lin,Xiaohui He,Jianping Xiong,Ping Li,Hongyun Zhao,Yan Huang,Yang Zhang,Likun Chen,Ningning Zhou,Yuanyuan Zhao,Xue Hou,Qing Yang,Li Zhang
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (10): 1338-1350 被引量:416
标识
DOI:10.1016/s1470-2045(18)30495-9
摘要

Summary

Background

Platinum-based doublet chemotherapy regimens, preferentially gemcitabine plus cisplatin, are generally considered the first-line standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma. However, no consensus has been reached regarding treatment following progression after first-line therapy. Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody. We present safety and preliminary antitumour activity of camrelizumab alone as second-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma and combined with gemcitabine and cisplatin as first-line therapy in this patient population.

Methods

We report the results from two single-arm, phase 1 trials. Both trials included patients aged 18–70 years with histologically or cytologically confirmed nasopharyngeal carcinoma and confirmed metastatic disease or locoreginal recurrence, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients who received at least one previous line of treatment were enrolled at five academic hospitals in China into the dose-escalation and expansion trial to receive camrelizumab monotherapy intravenously at escalating doses of 1 mg/kg, 3 mg/kg, and 10 mg/kg, and a bridging dose of 200 mg per dose once every 2 weeks (monotherapy trial). Treatment-naive patients were enrolled from a single centre in China to receive six cycles of camrelizumab 200 mg (day 1), gemcitabine 1 g/m2 (days 1 and 8), and cisplatin 80 mg/m2 (day 1) every 3 weeks followed by camrelizumab 200 mg maintenance once every 3 weeks (combination trial). The primary endpoint of both trials was the safety and tolerability of the study treatment. Analyses were done per protocol. Both trials are registered with ClinicalTrials.gov, number NCT02721589 (camrelizumab monotherapy trial) and NCT03121716 (camrelizumab combination trial). Both trials are ongoing, but are no longer enrolling patients.

Findings

In the camrelizumab monotherapy trial, between March 31, 2016, and Sept 20, 2017, 121 patients were assessed for eligibility, of whom 93 patients were enrolled across the dose-escalation and expansion cohorts and received at least one dose of camrelizumab (safety population). 15 (16%) of 93 patients had treatment-related adverse events of grade 3 or 4, the most common of which were elevated conjugated bilirubin concentration (three [3%] of 93 patients), stomatitis, anaemia, and increased concentrations of aspartate aminotransferase, alanine aminotransferase, and total bilirubin, each of which occurred in two (2%) patients. Eight (9%) patients had a treatment-related serious adverse event. No dose-limiting toxic effects were observed during the dose-escalation phase. 31 (34%; 95% CI 24–44) of 91 evaluable patients on camrelizumab monotherapy had an overall response with a median follow-up of 9·9 months (IQR 8·1–11·7). In the camrelizumab combination trial, between April 18, 2017, and Aug 15, 2017, 24 patients were assessed for eligibility, of whom 23 patients were enrolled and treated (safety population). 20 (87%) of 23 patients had grade 3 or 4 treatment-related adverse events: neutropenia (13 [57%] of 23 patients), anaemia (11 [48%] patients), leucopenia (11 [48%] patients), thrombocytopenia (seven [30%] patients), oedema (two [9%] patients), hyponatraemia (two [9%] patients), hypochloraemia (one [4%] patients), and rash (one [4%] patient). Two patients had treatment-related serious adverse events. No treatment-related deaths occurred in these trials. 20 (91% [95% CI 72–97]) of 22 evaluable patients had an overall response with a median follow-up time of 10·2 months (IQR 9·7–10·8).

Interpretation

Camrelizumab is a well tolerated, potential treatment option for patients with recurrent or metastatic nasopharyngeal carcinoma. The combination of camrelizumab plus gemcitabine and cisplatin has a manageable toxicity profile and promising preliminary antitumour activity for this disease in treatment-naive patients. Randomised controlled trials are needed to further establish the role of immune checkpoint inhibition for nasopharyngeal carcinomas.

Funding

Hengrui Medicine Co, Chinese National Natural Science Foundation project, Science and Technology Program of Guangdong, Pearl River Nova Program of Guangzhou.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
希望天下0贩的0应助View采纳,获得10
刚刚
梁不正完成签到,获得积分10
1秒前
legna发布了新的文献求助60
2秒前
SYLH应助WangZhen采纳,获得10
2秒前
AaronDP发布了新的文献求助10
3秒前
4秒前
顾矜应助淡然妙竹采纳,获得10
4秒前
KingYugene完成签到,获得积分10
4秒前
花藏影完成签到 ,获得积分10
5秒前
5秒前
Miranda完成签到,获得积分10
6秒前
SciGPT应助哈比人linling采纳,获得10
7秒前
kk119完成签到,获得积分10
7秒前
Coai517完成签到 ,获得积分10
8秒前
8秒前
小甘发布了新的文献求助10
9秒前
TG_FY完成签到,获得积分10
9秒前
yuan完成签到,获得积分10
10秒前
橙子完成签到,获得积分10
10秒前
谦让之云完成签到 ,获得积分10
10秒前
10秒前
愉快书琴完成签到,获得积分10
11秒前
11秒前
SYLH应助WangZhen采纳,获得10
12秒前
福尔摩云完成签到,获得积分10
13秒前
无辜的秀完成签到,获得积分10
14秒前
Charles完成签到,获得积分10
16秒前
hao发布了新的文献求助10
16秒前
小嘎发布了新的文献求助10
16秒前
ABin完成签到,获得积分10
18秒前
Jasper应助qixiaoqi采纳,获得10
18秒前
FangyingTang完成签到 ,获得积分10
19秒前
金枪鱼子完成签到,获得积分10
19秒前
theyoung发布了新的文献求助10
19秒前
20秒前
量子星尘发布了新的文献求助10
20秒前
赘婿应助liu采纳,获得10
20秒前
小马甲应助清仔采纳,获得10
20秒前
20秒前
luoyue完成签到,获得积分10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066